To examine whether promotion of the Hsp90–Acsl4 pathway also increased tumor sensitivity to erastin in vivo, we first established mouse subcutaneous and orthotopic models via PG7 cells to confirm the sensitivity of parental GBM cells to different concentrations of erastin (Supplementary Fig. 7A). This evidence concerns the gene ACSL4 and glioblastoma.